Clinical trial · Observational
A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with pancreatic cancer are treated with combinations of surgery, radiation therapy and chemotherapy, depending on the location of the cancer and other individual patient health factors. The goals of therapy are to reduce or eliminate the cancer cells, but without serious damage to normal cells. Investigators at The University of Michigan are conducting a research project, to see if treatment effects on an individual patient's cancer cells can be detected early by new imaging tests in patients with resectable pancreatic cancer undergoing neoadjuvant chemoradiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cohort
- description
- The majority of recruited patients will be treated on protocol HUM00004531 "A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer".
Primary outcomes (1)
- measure
- Diffusion MRI
- timeFrame
- 5 years
- description
- The goal is to develop a functional imaging method that would be a better predictor of pathological response than the current CT standard. Diffusion MRI has the potential to measure early cellular changes that occur in response to successful therapies, such as chemoradiation, and has been demonstrated to be an early predictor not only of therapeutic response, but also of overall survival for other malignancies.
Secondary outcomes (1)
- measure
- Apparent Diffusion Coefficient (ADC)
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologic or cytologic proof of pancreatic cancer, for whom the treatment plan, at the time of enrollment, is neoadjuvant chemoradiotherapy followed by surgical resection. * Patients must be \>18 years old. * Patients cannot weight over 300 pounds, the weight limit of the MRI table. * Patients must have adequate renal function (estimated glomerular filtration rate \> 60 mL/min/m2), to minimize the small risk of nephrogenic systemic sclerosis associated with gadolinium injection. * Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of UM hospital. Exclusion Criteria: * Patients must have no previous radiation to the abdomen. * Patients who are pregnant or lactating are excluded.
References
Publications (0)
Data not yet available